NCT03916094已完成1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of HLX22 Monoclonal Antibody Injection (HER2 Monoclonal Antibody) in Patients With Advanced Solid Tumours Overexpressing HER2
Shanghai Henlius Biotech1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2019年7月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2
研究概览
简要总结
a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX22 in patients with advanced solid tumors overexpressing HER2 after failure of standard of care.
详细描述
This study is an open-label and dose escalation study aimed at exploring the safety and MTD of HLX22.
three dose levels are designed for HLX22 in this study: 3, 10, and 25 mg/kg/3 weeks. The 3 mg/kg/3 weeks will serve as the starting dose. The study will use a 3+3 design to assign doses to the patients, and thereby determine the MTD of HLX22.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with child-bearing potential must agree to and be able to use effective contraceptive measures.
- •At least 28 days from prior major surgery, prior cytotoxic chemotherapy, prior hormonal therapy (except for androgen-deprivation therapy in patients with prostate cancer), prior therapy with investigational products (or medical device) or local radiotherapy, at least 42 days from prior chemotherapy with nitrosoureas or mitomycin C, and at least 42 days from prior immunotherapy before the first dose of HLX
- •At least one bi-dimensionally measurable lesion to be used as the basis for evaluation.
- •ECOG performance status of ≤ 1 at study entry. Patients with histologically-proven HER2-positive advanced or metastatic solid tumours who are either non-responsive or intolerant to standard therapies.
- •HER2-positive tumours that are confirmed by immunohistochemistry (IHC) and:
- •HER2 mutation of at least 3+ (+++) or
- •HER2 mutation of at least 2+ (++) and fluorescence in situ hybridization (FISH) test positive.
- •Adequate haematologic functions Adequate hepatic functions Adequate renal functions Adequate cardiac functions For patients with hepatocellular carcinoma, Child-Pugh score has to be A. Able to receive treatment and examinations as required by the study protocol. Life expectancy > 3 months. Exclusion Criteria Patients with history of alcohol or drug abuse, or positive for alcohol breath test before dosing.
- •Patients who still have ≥ Grade 2 toxicities from prior therapies (except for Grade 2 alopecia).
- •Concurrent unstable or uncontrolled medical conditions with either of the following:
- •Active systemic infections requiring intravenous antibiotic;
- •Poorly controlled hypertension, or poor compliance with anti-hypertensive agents;
- •Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (New York Heart Association [NYHA] Grade III or IV) or acute myocardial infarction within 6 months;
- •Uncontrolled diabetes mellitus or poor compliance with hypoglycemics;
- •NCI CTCAE Grade ≥ 2 hypercalcemia;
- •Presence of chronically unhealed wound or ulcers;
- •Other chronic diseases which, in the opinion of the Investigator, may compromise the safety of the patient or the integrity of the study.
- •Patients with history of interstitial lung disease. Patients with newly diagnosed or symptomatic brain metastases Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix (patients with a previous malignancy but without evidence of disease for ≥ 3 years can participate).
- •Patients have received a cumulative dose of doxorubicin (or equivalent) of ≥ 360 mg/m
- •Patients have participated in another clinical study within 4 weeks (in the case of a clinical study of a monoclonal antibody drug, 3 months or 5 half-lives, whichever is longer) prior to the enrolment, or patients have intended to participate in another clinical study during the period of the study.
- •Female patients in pregnancy (confirmed by ß-HCG test) or breastfeeding. Known history of human immunodeficiency virus (HIV) infection. Patients with active hepatitis B (positive for hepatitis B core antibody [HBcAb], or hepatitis B surface antigen [HBsAg], along with hepatitis B virus [HBV] DNA titre > the limit of normal defined by the study site), or hepatitis C (positive for hepatitis C antibody).
排除标准
- 未提供
研究组 & 干预措施
HLX22 group
Experimental
HLX22, at four dose levels (3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
干预措施: HLX22 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2
时间窗: from day1 to day 42(cycle 1 and cycle2 ,each cycle is 21days)
The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%).
次要结局
- the pharmacokinetic characteristics of HLX22 at different doses in patients.(cycle1 to cycle 8 ,and 28-day follow-up visit after the last infusion (if possible),(each cycle is 21 days).)
- the pharmacodynamic characteristics of HLX22 at different doses in patients(cycle 1 to cycle 6 (each cycle is 21 days))
- the immunogenicity of HLX22 in humans(cycle 1 to cycle 6 (each cycle is 21 days))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)Gastric CancerNCT05514158RemeGen Co., Ltd.24
Unknown
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsSolid TumorNCT03757936Shanghai Henlius Biotech30
招募中
1 期
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDSAMLNHLNCT06731699Chengdu FenDi Pharmaceutical Co., Ltd.72
已完成
1 期
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid TumorAdult Solid TumorNCT05400265Shanghai Henlius Biotech9
已完成
1 期
A Study of Intratumoral KL340399 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05549804Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.6